This Article Full Text Full Text (PDF) All Versions of this Article: 113/2/246    most recent CIRCULATIONAHA.105.558213v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lisy, O. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by Lisy, O. Articles by Burnett, J. C., Jr Related Collections Autonomic, reflex, and neurohumoral control of circulation Cardiovascular Pharmacology Other Research

(Circulation. 2006;113:246-251.)
© 2006 American Heart Association, Inc.

Heart Failure

New Cardioprotective Agent K201 Is Natriuretic and Glomerular Filtration Rate Enhancing

Ondrej Lisy, MD, PhD; John C. Burnett, Jr, MD

From the Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minn.

Correspondence to Ondrej Lisy, MD, PhD, Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905. E-mail lisy.ondrej{at}mayo.edu

Received April 25, 2005; revision received October 31, 2005; accepted November 7, 2005.

Background— K201 (JTV519) is a newly developed 1,4-benzothiazepine drug with antiarrhythmic and cardioprotective properties. It functions via stabilization of the ryanodine receptor–calcium release channel in the heart (RyR2). This receptor has been identified in the kidney, and in vitro studies suggest a role in the control of renal hemodynamics. To date, the in vivo function of this receptor is undefined. We hypothesized that this new drug, which is being developed for the treatment of heart failure for its myocardial actions, also possesses renal hemodynamic enhancing and excretory properties. We also used immunohistochemistry to identify RyR2 in the normal canine kidney.

Methods and Results— We investigated the renal actions of K201 during intrarenal infusion in normal anesthetized dogs. K201 was infused after baseline measurements at 2 doses (0.1 and 0.5 mg · kg^–1 · min^–1). Immunohistochemistry was used to identify RyR2 presence in the kidney not exposed to K201. K201 was potently natriuretic and diuretic, with glomerular filtration rate– and renal blood flow–enhancing actions. The excretory responses to K201 administration were associated with decreases in distal tubular reabsorption of sodium despite a mild decrease in mean arterial pressure, which returned to baseline levels after K201 discontinuation. Immunohistochemistry of the normal canine kidney revealed the presence of RyR2 in the medullary collecting duct cells.

Conclusions— We report for the first time that the newly developed cardioprotective drug K201 possesses natriuretic, diuretic, glomerular filtration rate–enhancing, and vasodilating properties that go beyond myocardial actions and may support its therapeutic role in treatment of heart failure.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				R. R.J. van Kimmenade, Y. Pinto, and J. L. Januzzi Jr When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'? Eur. Heart J., December 2, 2007; 28(24): 2960 - 2961. [Full Text] [PDF]